236 related articles for article (PubMed ID: 1715608)
1. New antipsychotics: classification, efficacy, and adverse effects.
Gerlach J
Schizophr Bull; 1991; 17(2):289-309. PubMed ID: 1715608
[TBL] [Abstract][Full Text] [Related]
2. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
4. [The atypical neuroleptic concept].
Azorin JM; Dassa D; Jalfre M
Encephale; 1992 Sep; 18 Spec No 3():453-7. PubMed ID: 1364079
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
6. Prospects for pharmacotherapy of schizophrenia.
Pickar D
Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
[No Abstract] [Full Text] [Related]
7. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
Kerwin RW
Br J Psychiatry; 1994 Feb; 164(2):141-8. PubMed ID: 7513599
[No Abstract] [Full Text] [Related]
8. The mechanism of action of novel antipsychotic drugs.
Meltzer HY
Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
[TBL] [Abstract][Full Text] [Related]
9. Novel antipsychotics and extrapyramidal side effects. Theory and reality.
Horácek J
Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():34-42. PubMed ID: 11072763
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
11. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone].
Niemegeers CJ; Awouters F; Janssen PA
Encephale; 1990; 16(2):147-51. PubMed ID: 1693560
[TBL] [Abstract][Full Text] [Related]
12. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.
Leucht S; Wahlbeck K; Hamann J; Kissling W
Lancet; 2003 May; 361(9369):1581-9. PubMed ID: 12747876
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Kapur S; Remington G
Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of dopamine research in schizophrenia.
Pani L
Curr Med Res Opin; 2002; 18 Suppl 3():s3-7. PubMed ID: 12418605
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
16. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
17. Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington G; Chong SA
J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
Leucht S
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
[TBL] [Abstract][Full Text] [Related]
19. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.
He H; Richardson JS
Int Clin Psychopharmacol; 1995 Mar; 10(1):19-30. PubMed ID: 7542676
[TBL] [Abstract][Full Text] [Related]
20. The evolution of the serotonin-dopamine antagonist concept.
Huttunen M
J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):4S-10S. PubMed ID: 7730499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
